Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Aspen has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Aspen bark and willow bark share the salicin family of phenolic glycosides. Gut bacteria hydrolyse both to saligenin, which the liver oxidises to salicylic acid. Taking them together raises total salicylate exposure from two sources rather than one, which matters when someone is counting a dose. Anyone already on a salicylate-containing product should count both.
Salicylic acid inhibits cyclooxygenase and lowers thromboxane production in platelets. EPA competes with arachidonic acid for the same enzyme and shifts eicosanoid output. Combined, the effect on platelet stickiness is additive rather than independent. Worth flagging before any procedure where bleeding time is relevant.
Gingerols and shogaols reduce thromboxane-driven platelet aggregation in laboratory work. Aspen bark contributes salicylate through the same eicosanoid route. The pairing is common in joint comfort formulas and the additive direction should be stated rather than assumed benign. This is mechanistic reasoning, not a measured clinical outcome in humans.
Nattokinase has fibrinolytic activity, and salicylate from aspen bark acts earlier on platelet aggregation. Different steps, same overall direction. Stacking them is a flag rather than a benefit claim. Read it as mechanistic.
Aspen bark carries condensed tannins, and polyphenols of that class form insoluble complexes with non-heme iron in the intestinal lumen. Less iron reaches the transporter as a result. Separating the two by a couple of hours is the usual formulation answer. This is a chemistry-level interaction, not a claim about iron status outcomes.
Boswellic acids act mainly on 5-lipoxygenase while salicylate acts on cyclooxygenase. The two branches of arachidonic acid handling are distinct, which is the usual rationale for pairing them in joint comfort and mobility products. Direct head to head data on the combination is thin. The pairing is formulation convention supported by mechanism.
Nothing specific on file for Aspen. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.12 sources behind our Aspen verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 295 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Aspen is, not how risky it is. A report is not proof Aspen caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.